Cargando…

Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors

Detalles Bibliográficos
Autores principales:	Chong, Pei Pei, Rubin, Joshua B., Abdullah, Maha, Conforti, Fabio, Klein, Sabra L., Liu, Wanli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244535/ https://www.ncbi.nlm.nih.gov/pubmed/35784358 http://dx.doi.org/10.3389/fimmu.2022.941254

Ejemplares similares

Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases
por: von Knethen, Andreas, et al.
Publicado: (2021)

Sex Differences in Immunity to Viral Infections
por: Jacobsen, Henning, et al.
Publicado: (2021)

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
por: Dermime, Said, et al.
Publicado: (2021)

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma
por: Shi, Fuyan, et al.
Publicado: (2021)

Sex — a potential factor affecting immune checkpoint inhibitor therapy for cancers
por: Hu, Wang, et al.
Publicado: (2022)

The Confluence of Sex Hormones and Aging on Immunity
por: Gubbels Bupp, Melanie R., et al.
Publicado: (2018)

The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies
por: González-Navajas, Jose M., et al.
Publicado: (2021)

Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review
por: Petrelli, Fausto, et al.
Publicado: (2021)

Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
por: Wong, Selina K., et al.
Publicado: (2021)

Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review
por: Li, Honglin, et al.
Publicado: (2023)

Editorial: Targeting metabolism to activate T cells and enhance the efficacy of checkpoint blockade immunotherapy in solid tumors
por: Xia, Zhijia, et al.
Publicado: (2023)

Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy
por: Bazhin, Alexandr V., et al.
Publicado: (2018)

Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors
por: Giordan, Quentin, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy
por: Silva, Saulo Brito, et al.
Publicado: (2022)

Analysis of Tumor Glycosylation Characteristics and Implications for Immune Checkpoint Inhibitor’s Efficacy for Breast Cancer
por: Lv, Wenchang, et al.
Publicado: (2022)

Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors
por: Jiang, Shuai, et al.
Publicado: (2022)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor
por: Hamada, Kazuyuki, et al.
Publicado: (2023)

Editorial: Soluble immune checkpoints: Novel physiological immunomodulators
por: Riva, Antonio
Publicado: (2023)

Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years
por: Zhang, Ping, et al.
Publicado: (2022)

Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma
por: Wang, Qi, et al.
Publicado: (2023)

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2023)

Editorial: ILC checkpoints: expression and functions in physiological and pathological conditions
por: Mariotti, Francesca Romana, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response
por: Yang, Fei, et al.
Publicado: (2022)

Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer
por: Lin, Anqi, et al.
Publicado: (2021)

Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study
por: Liu, Rong, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis
por: Noori, Maryam, et al.
Publicado: (2023)

Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study
por: Wei, Fuqun, et al.
Publicado: (2022)

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
por: Westdorp, Harm, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Human Glioma Microenvironment
por: Ghouzlani, Amina, et al.
Publicado: (2021)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

Cutaneous manifestations associated with immune checkpoint inhibitors
por: Watanabe, Tomoya, et al.
Publicado: (2023)

Editorial: Community series in immunotherapy with checkpoint inhibitors for non-small cell lung cancer, colon cancer, and esophageal cancer, volume II
por: Li, Yueyi, et al.
Publicado: (2023)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma
por: Xie, Fucun, et al.
Publicado: (2022)

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
por: Perrino, Matteo, et al.
Publicado: (2023)

Editorial: BCR Signaling and B Cell Activation
por: Liu, Wanli, et al.
Publicado: (2020)

Editorial: “The Role of Immune Checkpoint Molecules in Solid and Hematopoietic Stem Cell Transplantation”
por: Kordelas, Lambros, et al.
Publicado: (2021)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
por: Wang, Xueyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6ulfr100hqpcm35qh98n76k2ru